ImmunityBio, Inc. announced the treatment of patients in the U.S. with ANKTIVA for BCG-unresponsive bladder cancer. The FDA approved this immunotherapy on April 22, 2024.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
ImmunityBio, Inc. announced the treatment of patients in the U.S. with ANKTIVA for BCG-unresponsive bladder cancer. The FDA approved this immunotherapy on April 22, 2024.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.